Compare MGNX & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNX | SGC |
|---|---|---|
| Founded | 2000 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.4M | 214.8M |
| IPO Year | 2013 | 1994 |
| Metric | MGNX | SGC |
|---|---|---|
| Price | $2.41 | $13.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $8.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 968.0K | 22.1K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 4.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $149,500,000.00 | ★ $566,184,000.00 |
| Revenue This Year | N/A | $3.02 |
| Revenue Next Year | N/A | $3.83 |
| P/E Ratio | ★ N/A | $100.57 |
| Revenue Growth | N/A | ★ 0.09 |
| 52 Week Low | $1.32 | $8.30 |
| 52 Week High | $5.08 | $14.59 |
| Indicator | MGNX | SGC |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 55.19 |
| Support Level | $1.71 | $11.52 |
| Resistance Level | $3.46 | $13.66 |
| Average True Range (ATR) | 0.31 | 0.63 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 27.59 | 63.54 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.